Steven P Margossian
Overview
Explore the profile of Steven P Margossian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
634
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaminski J, Fleming R, Alvarez-Calderon F, Winschel M, McGuckin C, Ho E, et al.
Blood
. 2024 Apr;
144(1):46-60.
PMID: 38558106
Chimeric antigen receptor (CAR) T cells hold promise as a therapy for B-cell-derived malignancies, and despite their impressive initial response rates, a significant proportion of patients ultimately experience relapse. Although...
2.
Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris M, Prabhu S, et al.
Blood Adv
. 2022 Aug;
7(4):541-548.
PMID: 35938863
Remarkable complete response rates have been shown with tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy targeting CD19, in patients up to age 26 years with refractory/relapsed B-cell acute lymphoblastic...
3.
Severyn C, Siranosian B, Kong S, Moreno A, Li M, Chen N, et al.
JCI Insight
. 2022 Mar;
7(7).
PMID: 35239511
BACKGROUNDGut decontamination (GD) can decrease the incidence and severity of acute graft-versus-host disease (aGVHD) in murine models of allogeneic hematopoietic cell transplantation (HCT). In this pilot study, we examined the...
4.
Schultz L, Baggott C, Prabhu S, Pacenta H, Phillips C, Rossoff J, et al.
J Clin Oncol
. 2021 Dec;
40(9):945-955.
PMID: 34882493
Purpose: Tisagenlecleucel is a CD19-specific chimeric antigen receptor T-cell therapy, US Food and Drug Administration-approved for children, adolescents, and young adults (CAYA) with relapsed and/or refractory (RR) B-cell acute lymphoblastic...
5.
Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park J, et al.
Transplant Cell Ther
. 2021 Dec;
28(2):72.e1-72.e8.
PMID: 34852305
Chimeric antigen receptor (CAR) T cells achieve response and durable remission in patients with relapsed/refractory (R/R) B cell malignancies. Following collection of patient T cells, chemotherapy ("bridging chemotherapy") is utilized...
6.
Fabrizio V, Phillips C, Lane A, Baggott C, Prabhu S, Egeler E, et al.
Blood Adv
. 2021 Nov;
6(2):600-610.
PMID: 34794180
Chimeric antigen receptor (CAR) T cells have transformed the therapeutic options for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia. Data for CAR therapy in extramedullary (EM) involvement are limited. Retrospective data...
7.
Fabrizio V, Boelens J, Mauguen A, Baggott C, Prabhu S, Egeler E, et al.
Blood Adv
. 2021 Nov;
6(7):1961-1968.
PMID: 34788386
Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improves...
8.
Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips C, Stefanski H, et al.
Blood
. 2021 Sep;
138(21):2138-2142.
PMID: 34499715
No abstract available.
9.
Fabrizio V, Kernan N, Boulad F, Cancio M, Allen J, Higman M, et al.
Bone Marrow Transplant
. 2020 May;
55(11):2160-2169.
PMID: 32390002
To define the tolerability and outcome of allogeneic hematopoietic stem cell transplant (allo-HSCT) following CAR T-cell therapy, we retrospectively reviewed pediatric/young adult patients with relapsed/refractory B-ALL who underwent this treatment....
10.
Curran K, Margossian S, Kernan N, Silverman L, Williams D, Shukla N, et al.
Blood
. 2019 Oct;
134(26):2361-2368.
PMID: 31650176
Chimeric antigen receptor (CAR) T cells have demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We undertook a multicenter clinical trial to determine toxicity, feasibility,...